Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes

Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes.

Share this article: